|
1.
|
|
|
2.
|
|
|
Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis : A Randomized Double-Blind Controlled Trial
/
Ayats-Vidal, Roser (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Bosque, Montserrat (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Cordobilla, Begoña (Universitat de Barcelona) ;
Asensio-De la Cruz, Oscar (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
García-González, Miguel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Loureda-Pérez, Susana (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Fernández-López, Elena (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Robert-Barriocanal, Eva (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Valiente-Planas, Andrea (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Domingo, Joan Carles (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
A randomized, double-blind, and placebo-controlled study was conducted to assess the effect of dietary supplementation with high-rich docosahexaenoic acid (DHA) (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day in pediatric patients with cystic fibrosis (CF) as compared with placebo. [...]
2024 -  10.3390/nu16070970
Nutrients, Vol. 16 (march 2024)
|
|
|
3.
|
|
16 p, 1.9 MB |
Pituitary-Adrenal Axis and Peripheral Immune Cell Profile in Long COVID
/
Alijotas-Reig, Jaume (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Anunciación-Llunell, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Esteve-Valverde, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Morales-Pérez, Stephanie (Fundació Althaia) ;
Rivero-Santana, Sergio (Fundació Althaia) ;
Trapé, Jaume (Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central) ;
González-García, Laura (Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central) ;
Ruiz, Domingo (Fundació Althaia) ;
Marques-Soares, Joana Rita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Miró-Mur, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca)
In Long COVID, dysfunction in the pituitary-adrenal axis and alterations in immune cells and inflammatory status are warned against. We performed a prospective study in a cohort of 42 patients who suffered COVID-19 at least 6 months before attending the Long COVID unit at Althaia Hospital. [...]
2024 - 10.3390/biomedicines12030581
Biomedicines, Vol. 12 (march 2024)
|
|
|
4.
|
|
|
5.
|
|
12 p, 2.6 MB |
Highly dispersed Rh single atoms over graphitic carbon nitride as a robust catalyst for the hydroformylation reaction
/
Jurado, Lole (Université de Toulouse, France) ;
Esvan, Jerome (CIRIMAT, CNRS-INPT-UPS, Université de Toulouse, France) ;
Luque-Álvarez, Ligia A. (Centro Mixto CSIC-Universidad de Sevilla) ;
Bobadilla, Luis F. (Centro Mixto CSIC-Universidad de Sevilla) ;
Odriozola, José A. (Centro Mixto CSIC-Universidad de Sevilla) ;
Posada-Pérez, Sergio (Universitat de Girona) ;
Poater, Albert (Universitat de Girona) ;
Comas-Vives, Aleix (Universitat Autònoma de Barcelona. Departament de Química) ;
Axet, M. Rosa (Université de Toulouse, France)
Rhodium-catalysed hydroformylation, effective tool in bulk and fine-chemical synthesis, predominantly uses soluble metal complexes. For that reason, the metal leaching and the catalyst recycling are still the major drawbacks of this process. [...]
2023 - 10.1039/d2cy02094g
Catalysis science & technology, Vol. 13 (january 2023) , p. 1425-1436
|
|
|
6.
|
|
10 p, 203.8 KB |
Cancer Incidence in Heart Transplant Recipients with Previous Neoplasia History
/
Delgado-Jiménez, Juan Francisco (Hospital 12 de Octubre (Madrid)) ;
Alonso-Pulpón, L. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Mirabet Pérez, Sonia (Institut d'Investigació Biomèdica Sant Pau) ;
Almenar Bonet, Luis (Hospital Universitari i Politècnic La Fe (València)) ;
Pérez-Villa, Félix (Hospital Clínic i Provincial de Barcelona) ;
González-Vílchez, Francisco (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Palomo, J. (Hospital General Universitario Gregorio Marañón) ;
Blasco-Peiro, Teresa (Hospital Universitario Miguel Servet (Saragossa)) ;
Dolores García-Cosio, M. (Hospital 12 de Octubre (Madrid)) ;
González-Costello, J. (Hospital Universitari de Bellvitge) ;
de la Fuente Galán, Luis (Hospital Clínico Universitario de Valladolid) ;
Rábago Juan-Aracil, Gregorio (Clínica Universidad de Navarra) ;
Lage, E. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Pascual-Figal, Domingo Andrés (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Díaz-Molina, Beatriz (Hospital Universitario Central de Asturias) ;
Arizón, J. M (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Muñiz, Javier (Instituto Universitario de Ciencias de la Salud Instituto de Investigacion Biomedica de A Coruna. Universidade da Coruña) ;
Crespo-Leiro, Maria Generosa (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqualified patients from transplantation. Studies are needed to identify factors to be considered when deciding on the suitability of a patient with previous tumor for heart transplantation. [...]
2016 - 10.1111/ajt.13637
American Journal of Transplantation, Vol. 16 Núm. 5 (january 2016) , p. 1569-1578
|
|
|
7.
|
|
34 p, 950.5 KB |
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
/
Pasquini, Marcelo (Medical College of Wisconsin) ;
Zhang, Mei-Jie (Medical College of Wisconsin) ;
Medeiros, Bruno (Stanford University School of Medicine) ;
Armand, Philippe (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hu, Zhen-Huan (Medical College of Wisconsin) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Aljurf, Mahmoud D. (King Faisal Specialist Hospital Center and Research) ;
Akpek, Görgün (Banner MD Anderson Cancer Center) ;
Cahn, Jean-Yves (University Hospital) ;
Cairo, Mitchell S. (New York Medical College) ;
Cerny, Jan (UMass Memorial Medical Center) ;
Copelan, Edward A. (Carolinas HealthCare System) ;
Deol, Abhinav (Wayne State University) ;
Freytes, César O. (University of Texas Health Science Center San Antonio) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Medical Center) ;
George, Biju (Christian Medical College) ;
Gupta, Vikas (University Health Network) ;
Hale, Gregory A. (All Children's Hospital) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Klumpp, Thomas R. (Thomas Jefferson University Hospital) ;
Lazarus, Hillard M. (University Hospitals Case Medical Center) ;
Luger, Selina M. (University of Pennsylvania Medical Center) ;
Liesveld, Jane L. (University of Rochester Medical Center) ;
Litzow, Mark Robert (Mayo Clinic) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Norkin, Maxim (University of Florida College of Medicine) ;
Olsson, Richard F. (Uppsala University) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Pawarode, Attaphol (University of Michigan) ;
Pulsipher, Michael A. (University of Southern California Keck School of Medicine) ;
Ramanathan, Muthalagu (UMass Memorial Medical Center) ;
Reshef, Ran (University of Pennsylvania Medical Center) ;
Saad, Ayman A. (University of Alabama at Birmingham) ;
Saber, Wael (Medical College of Wisconsin) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Schouten, Harry C. (Academische Ziekenhuis) ;
Ringdén, Olle (Centre for Allogeneic Stem Cell Transplantation) ;
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center) ;
Uy, Geoffrey L. (Washington University School of Medicine) ;
Wood, William A. (University of North Carolina) ;
Wirk, Baldeep (Seattle Cancer Care Alliance) ;
Pérez, Waleska S. (Medical College of Wisconsin) ;
Batiwalla, Minoo (National Heart Lung and Blood Institute - National Institutes of Health) ;
Weisdorf, Daniel J. (University of Minnesota Medical Center) ;
Universitat Autònoma de Barcelona
The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. [...]
2016 - 10.1016/j.bbmt.2015.08.024
Biology of blood and marrow transplantation, Vol. 22 Núm. 2 (january 2016) , p. 248-257
|
|
|
8.
|
|
24 p, 3.2 MB |
An electrostatically conjugated-functional MNK1 aptamer reverts the intrinsic antitumor effect of polyethyleneimine-coated iron oxide nanoparticles in vivo in a human triple-negative cancer xenograft
/
Mulens-Arias, Vladimir (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Portilla, Yadileiny (Centro Nacional de Biotecnología) ;
Pérez Yagüe, Sonia (Centro Nacional de Biotecnología) ;
Ferreras Martín, Raquel (IRYCIS-Hospital Universitario Ramón y Cajal) ;
Martín, María Elena (IRYCIS-Hospital Universitario Ramón y Cajal) ;
González, Víctor M. (IRYCIS-Hospital Universitario Ramón y Cajal) ;
Barber, Domingo F. (Centro Nacional de Biotecnología)
Background: Triple-negative breast cancer (TNBC) remains a difficult breast cancer subtype to treat as it exhibits a particularly aggressive behavior. The dysregulation of distinct signaling pathways underlies this aggressive behavior, with an overactivation of MAP kinase interacting kinases (MNKs) promoting tumor cell behavior, and driving proliferation and migration. [...]
2023 - 10.1186/s12645-023-00204-8
Cancer Nanotechnology, Vol. 14 Núm. 1 (december 2023) , p. 64
|
|
|
9.
|
|
21 p, 14.7 MB |
Interaction of Iron Oxide Nanoparticles with Macrophages Is Influenced Distinctly by "Self" and "Non-Self" Biological Identities
/
Portilla, Yadileiny (Department of Immunology and Oncology and Nanobiomedicine Initiative. Centro Nacional de Biotecnología (CNB-CSIC)) ;
Mulens-Arias, Vladimir (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Daviu, Neus (Centro Nacional de Biotecnología) ;
Paradela, Alberto (Centro Nacional de Biotecnología) ;
Pérez Yagüe, Sonia (Department of Immunology and Oncology and Nanobiomedicine Initiative. Centro Nacional de Biotecnología (CNB-CSIC)) ;
Barber, Domingo F. (Centro Nacional de Biotecnología)
Upon contact with biological fluids like serum, a protein corona (PC) complex forms on iron oxide nanoparticles (IONPs) in physiological environments and the proteins it contains influence how IONPs act in biological systems. [...]
2023 - 10.1021/acsami.3c05555
ACS applied materials & interfaces, Vol. 15 Núm. 30 (february 2023) , p. 35906-35926
|
|
|
10.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
